ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation
Go back to ELIQUIS Receives FDA Approval in Reducing Certain Risks in Nonvalvular Atrial Fibrillation| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 49.31 +0.17 (0.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $49.14 | 52 Week High | $77.12 | |||
| Open | $49.16 | 52 Week Low | $49.03 | |||
| Day High | $49.47 | P/E | 32.02 | |||
| Day Low | $48.96 | EPS | $1.54 | |||
| Volume | 498,918 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 26.38 +0.12 (0.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.26 | 52 Week High | $37.39 | |||
| Open | $26.33 | 52 Week Low | $28.25 | |||
| Day High | $26.40 | P/E | 15.99 | |||
| Day Low | $26.26 | EPS | $1.65 | |||
| Volume | 1,920,879 | |||||
